Vascular co-option in lung cancer metastatic to the eye after treatment with bevacizumab

Efrem D. Mandelcorn, Alan G. Palestine, Sander Dubovy, Janet L Davis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Chemotherapy with bevacizumab alters the angiogenic environment, and therefore, the growth and spread of metastases. We present a patient with metastatic lung adenocarcinoma to the eye with findings suggestive of retinal vascular co-option. Methods: Case report. Results: A 57-year-old male, receiving systemic bevacizumab for metastatic lung adenocarcinoma, presented with vitreous opacities and clumped deposits adherent to the retinal vessels. No choroidal metastases were present. Diagnostic vitrectomy yielded cellular evidence of adenocarcinoma, with thyroid transcription factor-1 staining confirming a lung primary. Conclusion: The perivascular growth of small foci of metastatic vitreous cells suggests vascular co-option from the native retinal circulation. Similar modification of metastatic disease by bevacizumab has been observed in animal models and selected human cases.

Original languageEnglish
Pages (from-to)35-38
Number of pages4
JournalJournal of Ophthalmic Inflammation and Infection
Volume1
Issue number1
DOIs
StatePublished - Mar 1 2011

Fingerprint

Blood Vessels
Retinal Vessels
Lung Neoplasms
Neoplasm Metastasis
Vitrectomy
Growth
Adenocarcinoma
Therapeutics
Animal Models
Staining and Labeling
Drug Therapy
Lung
Bevacizumab
Adenocarcinoma of lung
thyroid nuclear factor 1

Keywords

  • Angiogenesis
  • Bevacizumab
  • Metastatic lung carcinoma
  • Retina
  • Vascular co-option
  • Vitreous

ASJC Scopus subject areas

  • Ophthalmology
  • Infectious Diseases

Cite this

Vascular co-option in lung cancer metastatic to the eye after treatment with bevacizumab. / Mandelcorn, Efrem D.; Palestine, Alan G.; Dubovy, Sander; Davis, Janet L.

In: Journal of Ophthalmic Inflammation and Infection, Vol. 1, No. 1, 01.03.2011, p. 35-38.

Research output: Contribution to journalArticle

@article{48aa74c735d94df1adb8371f5a4de8f5,
title = "Vascular co-option in lung cancer metastatic to the eye after treatment with bevacizumab",
abstract = "Background: Chemotherapy with bevacizumab alters the angiogenic environment, and therefore, the growth and spread of metastases. We present a patient with metastatic lung adenocarcinoma to the eye with findings suggestive of retinal vascular co-option. Methods: Case report. Results: A 57-year-old male, receiving systemic bevacizumab for metastatic lung adenocarcinoma, presented with vitreous opacities and clumped deposits adherent to the retinal vessels. No choroidal metastases were present. Diagnostic vitrectomy yielded cellular evidence of adenocarcinoma, with thyroid transcription factor-1 staining confirming a lung primary. Conclusion: The perivascular growth of small foci of metastatic vitreous cells suggests vascular co-option from the native retinal circulation. Similar modification of metastatic disease by bevacizumab has been observed in animal models and selected human cases.",
keywords = "Angiogenesis, Bevacizumab, Metastatic lung carcinoma, Retina, Vascular co-option, Vitreous",
author = "Mandelcorn, {Efrem D.} and Palestine, {Alan G.} and Sander Dubovy and Davis, {Janet L}",
year = "2011",
month = "3",
day = "1",
doi = "10.1007/s12348-010-0013-7",
language = "English",
volume = "1",
pages = "35--38",
journal = "Journal of Ophthalmic Inflammation and Infection",
issn = "1869-5760",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Vascular co-option in lung cancer metastatic to the eye after treatment with bevacizumab

AU - Mandelcorn, Efrem D.

AU - Palestine, Alan G.

AU - Dubovy, Sander

AU - Davis, Janet L

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background: Chemotherapy with bevacizumab alters the angiogenic environment, and therefore, the growth and spread of metastases. We present a patient with metastatic lung adenocarcinoma to the eye with findings suggestive of retinal vascular co-option. Methods: Case report. Results: A 57-year-old male, receiving systemic bevacizumab for metastatic lung adenocarcinoma, presented with vitreous opacities and clumped deposits adherent to the retinal vessels. No choroidal metastases were present. Diagnostic vitrectomy yielded cellular evidence of adenocarcinoma, with thyroid transcription factor-1 staining confirming a lung primary. Conclusion: The perivascular growth of small foci of metastatic vitreous cells suggests vascular co-option from the native retinal circulation. Similar modification of metastatic disease by bevacizumab has been observed in animal models and selected human cases.

AB - Background: Chemotherapy with bevacizumab alters the angiogenic environment, and therefore, the growth and spread of metastases. We present a patient with metastatic lung adenocarcinoma to the eye with findings suggestive of retinal vascular co-option. Methods: Case report. Results: A 57-year-old male, receiving systemic bevacizumab for metastatic lung adenocarcinoma, presented with vitreous opacities and clumped deposits adherent to the retinal vessels. No choroidal metastases were present. Diagnostic vitrectomy yielded cellular evidence of adenocarcinoma, with thyroid transcription factor-1 staining confirming a lung primary. Conclusion: The perivascular growth of small foci of metastatic vitreous cells suggests vascular co-option from the native retinal circulation. Similar modification of metastatic disease by bevacizumab has been observed in animal models and selected human cases.

KW - Angiogenesis

KW - Bevacizumab

KW - Metastatic lung carcinoma

KW - Retina

KW - Vascular co-option

KW - Vitreous

UR - http://www.scopus.com/inward/record.url?scp=84862975932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862975932&partnerID=8YFLogxK

U2 - 10.1007/s12348-010-0013-7

DO - 10.1007/s12348-010-0013-7

M3 - Article

C2 - 21475657

AN - SCOPUS:84862975932

VL - 1

SP - 35

EP - 38

JO - Journal of Ophthalmic Inflammation and Infection

JF - Journal of Ophthalmic Inflammation and Infection

SN - 1869-5760

IS - 1

ER -